Millennium Pharmaceuticals
E852353
Millennium Pharmaceuticals is a biotechnology company known for developing innovative cancer therapies, including the proteasome inhibitor bortezomib (Velcade) for multiple myeloma.
Observed surface forms (3)
| Surface form | Occurrences |
|---|---|
| Velcade | 0 |
| bortezomib | 0 |
| Takeda Oncology | 0 |
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
biotechnology company
ⓘ
cancer drug ⓘ drug ⓘ oncology business unit ⓘ proteasome inhibitor ⓘ |
| acquiredBy | Takeda Pharmaceutical Company NERFINISHED ⓘ |
| activeIngredient | bortezomib NERFINISHED ⓘ |
| alternativeName | Millennium: The Takeda Oncology Company NERFINISHED ⓘ |
| collaboratesWith |
academic research institutions
ⓘ
other pharmaceutical companies ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| developed |
Velcade
NERFINISHED
ⓘ
bortezomib ⓘ |
| engagesIn |
clinical trials
ⓘ
translational research ⓘ |
| focusesOn |
cancer therapeutics
ⓘ
hematologic malignancies ⓘ oncology ⓘ |
| headquartersLocation | Cambridge, Massachusetts NERFINISHED ⓘ |
| indication |
mantle cell lymphoma
ⓘ
multiple myeloma ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| knownFor |
Velcade
NERFINISHED
ⓘ
development of bortezomib ⓘ |
| locatedIn |
Massachusetts
ⓘ
United States of America ⓘ
surface form:
United States
|
| mechanismOfAction | proteasome inhibition ⓘ |
| parentCompany | Takeda Pharmaceutical Company NERFINISHED ⓘ |
| partOf | Takeda Oncology NERFINISHED ⓘ |
| productType |
hematology drugs
ⓘ
oncology drugs ⓘ |
| regulatoryAgencyApproval | U.S. Food and Drug Administration NERFINISHED ⓘ |
| regulatoryApprovalFor | Velcade NERFINISHED ⓘ |
| researchFocus |
proteasome inhibition
ⓘ
small-molecule drugs ⓘ targeted therapies ⓘ |
| routeOfAdministration |
intravenous
ⓘ
subcutaneous ⓘ |
| specializesIn |
clinical development
ⓘ
drug discovery ⓘ |
| therapeuticArea |
mantle cell lymphoma
ⓘ
mantle cell lymphoma ⓘ multiple myeloma ⓘ multiple myeloma ⓘ |
| tradeName | Velcade NERFINISHED ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.